8. **Spada M**, Pagliardini S, Yasuda M, Tukul T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. *Am J Hum Genet* 2006;**79**:31–40.
9. **Schiffmann R**, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 2001;**285**:2743–9.
10. **Eng CM**, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. *Am J Hum Genet* 2001;**68**:711–22.
11. **West M**, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. Agalsidase alfa and kidney dysfunction in Fabry disease. *J Am Soc Nephrol* 2009;**20**:1132–9.
12. **Eng CM**, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. *Genet Med* 2006;**8**:539–48.
13. **Beck M**. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. *Acta Paediatr Suppl* 2006;**95**:43–6.
14. **Giannini EH**, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. *Mol Genet Metab* 2010;**99**:283–90.
15. **Hughes DA**. The use of scoring systems in patients with haematological malignancy. *Acta Paediatr Suppl* 2006;**95**:47–51.
16. **Devereux RB**, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986;**57**:450–8.
17. **Levey AS**, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;**130**:461–70.
18. **Moore DF**, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. *Pharmacoeconomics* 2007;**25**:201–8.
19. **Barba-Romero MA**, Deegan P, Giugliani R, Hughes D. Does geographical location influence the phenotype of Fabry disease in women in Europe? *Clin Genet* 2010;**77**:131–40.
20. **Thadhani R**, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT. Patients with fabry disease on dialysis in the United States. *Kidney Int* 2002;**61**:249–55.
21. **Mehta A**, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Lid-ove O. Therapeutic goals in the treatment of Fabry disease. *Genet Med* 2010;**12**:713–20.

Correction

Axenovich T, Zorkoltseva I, Belonogova N, *et al.* Linkage and association analyses of glaucoma related traits in a large pedigree from a Dutch genetically isolated population. *J Med Genet* 2011;**48**:802–9. doi:10.1136/jmedgenet-2011-100436. The names of the authors from The Netherlands should be: van Koolwijk LME, Ramdas WD, Amin N, Despriet DDG, Vingerling JR, Lemij HC, Oostra BA, Klaver CCW, Aulchenko YS, van Duijn CM.

J Med Genet 2012;**49**:220. doi:10.1136/jmedgenet-2011-100436corr1